Purpose: Evaluation of target coverage and verification of safety margins, in motion management strategies implemented by Lung Optimized Treatment (LOT) module in CyberKnife system. Methods: Three fiducial-less motion management strategies provided by LOT can be selected according to tumor visibility in the X ray images acquired during treatment. In 2-view modality the tumor is visible in both X ray images and full motion tracking is performed. In 1-view modality the tumor is visible in a single X ray image, therefore, motion tracking is combined with an internal target volume (ITV)-based margin expansion. In 0-view modality the lesion is not visible, consequently the treatment relies entirely on an ITV-based approach.
INTRODUCTION
Stereotactic body radiotherapy (SBRT) is the preferred treatment option for inoperable lung tumors, given its limited treatment-related toxicity and its good local control rates. [1] [2] [3] [4] Moreover, it is recently considered as a viable treatment option also for operable lung patients. 5 However, lung tumors are prone to motion (mainly caused by respiration) that affects both intrafractional and interfractional radiation delivery. 6 The management of respiratory motion in lung SBRT is essential to achieve high therapeutic ratio, ensuring adequate coverage of the moving target volume while sparing the surrounding critical structures. The amount of irradiated volume depends on the applied motion management strategy and on the adopted safety margins. 7 The main aim of this study was providing a quantitative evaluation of target coverage, as a function of planning target volume margins, in the three fiducial-less motion management strategies implemented by Lung Optimized Treatment (LOT) module in CyberKnife â system (Accuray, Inc., Sunnyvale, CA, USA). We pursued such aim through retrospective analysis of pre-treatment information derived from 4DCT-based planning and in-treatment data extracted from log files.
MATERIALS AND METHODS

2.A. Lung optimized treatment (LOT) module of CyberKnife system
Recently, CyberKnife â system (Accuray, Inc., Sunnyvale, CA, USA) has been equipped with Lung Optimized Treatment (LOT) module (Fig. 1) . It provides three fiducial-less motion management strategies, to be selected according to tumor visibility in the X ray images acquired during treatment: (a) dynamic tumor tracking (2-view modality), (b) internal target volume (ITV)-based approach (0-view modality) and (c) combined tracking and ITV-based approach (1-view modality).
In 2-view modality, the tumor is localized in both orthogonal X ray images and three-dimensional (3D) motion tracking is performed as in Xsight Lung Tracking TM . 8, 9 In 0-view modality, the tumor cannot be detected in either of the X ray images and consequently the treatment relies entirely on an ITV-based approach, using Xsight Spine tracking TM for patient alignment. 10, 11 The irradiated volume encompasses tumor motion, as detected by pre-treatment four-dimensional computed tomography (4D-CT). In 1-view modality, the tumor is visible in only one of the X ray projections (A or B) and dynamic tumor tracking compensates the target motion only in the detectable plane. Non-visible motion is compensated with an ITVbased strategy. Therefore, less normal tissue is exposed to radiation compared to the ITV-based approach. Usually, the visibility of the target in the X ray images, and thus the selection of motion management modalities, depends on target size, density and location. 8, 10, 12 At our Institution about 55% of lung patients undergoing CyberKnife SBRT are treated in 0-view modality, 27% in 1-view modality and 18% in 2-view-modality. 13 
2.B. Patient data
This study included data from 30 patients, treated for lung tumors with CyberKnife in 2-view modality from November 2014 to February 2017. The study was performed within the Institutional Ethics Committee notification regarding stereotactic body radiotherapy and image-guided radiotherapy (notification n°93/11). The patients gave written informed consent for radiotherapy and for the use of their anonymized data for educational and research purposes.
At the time of radiation treatment, the median patient age was 76 yr (range: 46-87 yr). Thirteen patients reported respiratory disorders, mainly chronic obstructive pulmonary disease.
Planning 4D-CT was acquired by GE Optima CT580 W scanner (GE Healthcare, Chicago, IL, USA) featuring 1.25 mm slice thickness and 1.27 mm pixel spacing. The Real-time Position Management system (RPM, Varian, Palo Alto, USA) was used for amplitude-based sorting. Full-inhale and full-exhale phases were considered for treatment planning. At our Institution, the planning target volume (PTV) in 2-view modality was defined as 3 mm isotropic expansion of the exhale clinical target volume (CTV). We choose the exhale phase as a reference state as it is the most reproducible and representative phase of free breathing since tumor spent more time in the exhalation than in the inhalation phase.
14 All patients were positioned using a customized external vacuum-type cast. The size of the CyberKnife collimator varied between 25 and 60 mm and was comparable to the size of the lesion ensuring the PTV irradiation along its entire movement. Treatment consisted of 3-5 fractions to a total dose ranging from 18 to 54 Gy, prescribed to the isodose of 80% of prescription dose.
Data including the 3D co-ordinates of the target over the course of treatment were extracted from the treatment log files and used to determinate the actual target motion in the three anatomical directions [latero-lateral (LL), anterior-posterior (AP) or superior inferior (SI)]. 6, 12, [15] [16] [17] [18] [19] [20] [21] Multiplan (version 5.2 Accuray) was used for treatment planning and data analysis was performed with MATLAB â (MathWorks, Natick, MA) and Plastimatch 22 .
2.C. Tumor motion evaluation
The amplitude of respiratory motion was measured in 4D-CT data as the distance between the centre of mass of the CTV in the exhale and inhale positions. During treatment, peak-to-peak respiratory amplitude was derived from the tumor positions estimated by the correlation model, according to the method proposed by Lu et al. 23 The Kruskal-Wallis and Wilcoxon rank-sum tests at 1% significance level investigated differences among motion amplitudes in different anatomical directions, as well as the correspondence between pre-treatment motion amplitude and the median motion amplitude during treatment. Dependence of respiratory motion amplitudes on tumor location and CTV volume was evaluated using Spearman correlation coefficient.
2.D. Correlation and overall tracking error
The correlation error was defined as the discrepancy between the target position estimated by the correlation model and the position measured by the X ray images during treatment delivery. The overall tracking error considered the predicted target position, thus including both correlation and temporal prediction uncertainties. The dependency of such errors on target motion amplitude in each anatomical direction was investigated through Spearman correlation coefficient.
2.E. Coverage evaluation
CTV coverage was investigated to provide a quantitation of the treatment geometric accuracy. It was calculated in correspondence to each control image acquired during irradiation as the intersection between the CTV centred on the imaged target position (serving as ground-truth) and the PTV centred on the predicted target position, as recorded in log files. In this way, we define the coverage of each voxel of the CTV as the percentage of control images where such voxel was included in the irradiated volume (i.e., PTV), as exemplified in Figs. 2(a) and 2(b).
The coverage analysis was carried out for the 2-view modality as described above and for simulated 1-view and 0-view modalities. To simulate 1-view and 0-view treatment delivery modalities we took advantage of the 2-view tracking data extracted from the treatment log files providing 3D coordinates of the target over the course of treatment. CTV coverage in 1-view and 0-view was calculated as described hereafter.
In the 1-view case, tracking is restricted on the plane perpendicular to the active camera's axis (in-plane directions). Consequently, the ITV-1-view was defined as the envelope of the CTV volume at inhale and exhale positions along the camera axis, that is, encompassing only the outof-plane target motion, which cannot be imaged since it is parallel to the camera axis (out-of-plane direction). In this scenario, the PTV was obtained, according to the protocol of our Institution, through an anisotropic margin applied to the ITV-1-view: 3 mm in-plane and 5 mm in out-of-plane directions. To simulate planar tracking, predicted target locations extracted from log files were projected on inplane directions. Then, coverage was calculated as the intersection between the CTV centred on the imaged target position and the PTV centred on the projected predictor data.
In 0-view treatments, tracking is disabled. Therefore, the ITV was defined as the envelope of the CTV at the inhale and the exhale phase of the planning 4D CT. Then, the PTV was derived by 5 mm isotropic margin expansion from the ITV. In this case, we computed CTV coverage as the intersection between the CTV centred on the imaged target position and the non-moving PTV.
Similar to cumulative dose-volume histograms, coveragevolume histograms (CVH) were derived from volumetric coverage distributions. The coverage of the 90% and the 95% of CTV volume (C90 and C95) were chosen as a CVH evaluation metrics [ Fig. 2(c) ]. CVH, C90 and C95 values were derived for each patient and for the three LOT modalities: 2-view, 1-view (simulating both 1-View-A and 1-View-B scenarios depending on the active camera) and 0-view.
We considered the coverage of 95% of CTV volume greater than 95% (C95 ≥ 95%) as a threshold to determine whether the applied margin ensured adequate coverage of the target volume. 7, 12, 17 The Kruskal-Wallis test was applied to C90 and C95 distributions to compare target coverage obtained with the different modalities. Furthermore, the influence of tumor position on coverage was investigated with the Wilcoxon rank-sum test.
2.F. Margin optimization
We adopted the above-mentioned margin evaluation criterion (C95 ≥ 95%) to apply an a-posteriori margin optimization on a patient-specific basis.
In the 2-view modality, the CTV volume was gradually expanded by adding 1 mm isotropic margins until reaching C95 ≥ 95%. The 0-view modality was treated in the same way, but the incremental margins were applied to the ITV.
For the 1-view modality, in accordance to the current clinical protocol, we adopted an anisotropic margin optimization approach: the ITV-1 view (as defined in the previous paragraph) was progressively expanded evaluating each combination of in-plane and out-of-plane margin between 2 and 12 mm, then choosing the combination that satisfies the C95 ≥ 95% criterion minimizing the final volume of the PTV.
For each patient, the optimal margin was computed for each modality and the resulting volume of PTV volume was compared against the CTV volume to provide a synthetic measurement of the expansion required to obtain adequate coverage.
RESULTS
A total of 96 treatment fractions corresponding to an average total treatment time over fractions per patients of 64 min (range: 31-156 min, from the first to the last treatment node) . In this exemplification, about 17% of the volume receives 100% coverage, whereas 62% of the volume receives at least 66% coverage and 100% of the volume has a coverage equal or larger than 33%. C95 is 33%, meaning that 95% of the volume shows a coverage of at least 33%.
[ 
3.A. Tumor motion evaluation
For all patients, the respiratory motion measured in the 4D-CT was 0.6 AE 1.0 mm (median AE IQR), 1.2 AE 1.7 mm and 4.2 AE 6.0 mm in LL, AP and SI direction, respectively. Respiratory amplitude during treatment was 0.9 AE 1.0 mm, 1.2 AE 1.6 mm and 4.6 AE 8.3 mm in LL, AP and SI direction, respectively. The predominant direction of tumor motion was SI both in the 4D-CT analysis and in treatment log files analysis (P ( 0.01).
Median SI motion amplitude was significantly larger in lower/middle lobes compared to the upper lobe both in 4D-CT scenario and during treatment (P ( 0.01). Motion amplitude was not significantly different (P > 0.09) between 4D-CT scenario and during treatment.
No dependence of median motion amplitude on CTV volume was found (R < 0.5, P > 0.01) neither in 4D-CT study nor during treatment. Similarly, no dependence on the distance from the spine was found (R < 0.5, P > 0.01).
3.B. Correlation and overall tracking error
The median AE IQR of the correlation error of all patients was 0.5 AE 0.7 (95th percentile: 1.9) mm, 0.6 AE 0.9 (2.7) mm, 0.7 AE 1.1 (3.6) mm in LL, AP and SI direction, respectively. Overall tracking errors were almost identical to correlation errors: 0.5 AE 0.7 (1.9) mm in LL direction, 0.6 AE 0.9 (2.7) mm in AP and 0.8 AE 1.3 (3.7) mm in SI.
Correlation was found between the correlation error and tumor motion amplitudes captured during irradiation in AP (R = 0.57, P = 0.001) and SI (R = 0.81, P ( 0.01) directions. Similarly, correlation was found between overall tracking error and amplitudes during treatment in AP (R = 0.54, P = 0.002) and SI (R = 0.84, P =( 0.01) directions.
3.C. Coverage evaluation
The CVHs obtained for each LOT modality and each patient are shown in Fig. 3 while the CVH evaluation metrics (C90 and C95) are summarized in Table I and extensively  shown in Supporting Information Table S1 .
Even if median C95 and C90 were slightly smaller for 2-view treatments with respect to 1-view and 0-view, no statistically significant difference were observed among the C90 and C95 population corresponding to the three modalities (P = 0.42 and P = 0.52 respectively). Target coverage was equally guaranteed in the different treatment modalities.
Considering the treatment modalities altogether, we observed that C90 and C95 depended on the tumor position in the lung. The Wilcoxon rank-sum test showed significant difference between the two populations corresponding to upper lobe and lower/middle lobe (P ( 0.001 for both C90 and C95). The median AE IQR of C90 for upper lobe lesions was 99.1 AE 0.6% (range: 55.0-99.1%), whereas it was 98.9 AE 4.2% (range: 73.1-99.1%) for lower and middle lobe tumors. Similarly, the median AE IQR of C95 for upper lobe lesions was 99.0 AE 3.1% (range: 52.9-99.1%), whereas it was 97.8 AE 7.5% (range: 60.9-99.1%) for lower and middle lobe tumors.
In 2-view scenario, the current prescription of 3 mm isotropic margins expansion around the CTV in end-exhale ensured C95 ≥ 95% in 21/30 (70%) patients. Among the nine patients who did not meet the criterion of C95 ≥ 95%, only three patients had C95 ≤ 90%. In these patients, tumors were located in the middle and lower lobes and motion excursion measured in the 4D-CT were greater than the median motion excursion of the population. These patients exhibited C95 ≤ 90% also in the other treatment modalities.
In Fig. 4 , the CTV coverage in 2-view modality is reported for the patient showing the worst C95 within the population (C95 = 77.2%).
In the simulated 1-view scenario, in-plane expansion of 3 mm and out-of-plane expansion of 5 mm ensured adequate CTV coverage (C95 ≥ 95%) in 51/60 (85%) of 1-view cases (A-B). In particular, five patients exhibited C95 ≤ 90%.
Finally, in the simulated 0-view scenario, 5 mm isotropic margin expansion around the ITV ensured adequate CTV coverage in 19 (63%) patients. Among the nine patients who did not meet the criterion of C95 ≥ 95%, five patients exhibited C90 and C95 ≤ 90%.This was probably due to prolonged irregularities in the breathing pattern during irradiation).
3.D. Margin optimization
Margin optimization results are reported in Fig. 5 . In 2-view scenario, margin expansion of the CTV could be reduced to 2 mm, still ensuring C95 ≥ 95% in 10 (33%) patients. However, in nine (30%) patients, a larger margin (up to 7 mm) was required to meet the above-mentioned criterion.
Considering the simulated 1-view scenario, 3 mm margin expansion in in-plane and out-of-plane directions allowed to achieve the desired converge in 71.7% of the cases (considering 1-view-A and 1-view-B altogether). Nevertheless, in a single instance a very large margin (isotropic 10 mm) was required.
Finally, in the simulated 0-view scenario, in 18 (60%) patients, margin expansion could be reduced still ensuring target coverage. However, in 11 (37%) patients larger margins were necessary to ensure at least 95% of coverage to the 95% of CTV volume.
The Kruskal-Wallis test did not report any significant difference between volumes of PTV defined according to the current prescriptions and those obtained through patientspecific margin optimization for each treatment modalities (P > 0.7). In both 2-view and 1-view modality, optimal margin resulted in slightly larger PTV volume, whereas the opposite behavior was observed in 0-view cases.
DISCUSSION
In this work, we considered data from 30 patients treated with CyberKnife LOT. Through the quantitation of the CTV geometric coverage, we investigated the adequacy of the PTV margins applied in our Institution simulating different treatment modalities (2-view, 1-view and 0-view). Results showed that such margins ensure the required target coverage in the majority of the cases.
A preliminary analysis of tumor motion was performed. The respiratory amplitude measured with planning 4D-CT and with online tumor tracking data was in agreement with previously published studies. 6, 12, 14, 23, 24 In addition, motion amplitudes captured with 4D-CT were representative of median excursions measured during treatment for each anatomical direction and in each lung lobe. 23, [25] [26] [27] This confirms that the ITV, defined during treatment planning as the envelope of exhale and inhale CTV, is a robust approximation of tumor Median AE IQR (range) (%) motion observed during irradiation, despite inter-and intrafractional variations. Several retrospective studies calculated the uncertainty in radiation delivery (i.e., tumor tracking errors) by analysing dynamic tracking log files produced by the CyberKnife system. 12, [15] [16] [17] [18] [19] [20] 28, 29 Our results were in agreement with these works: limited tracking errors (median < 1 mm) were observed in all directions and a significant correlation was found between the errors magnitude and motion amplitude.
An investigation into tumor motion associated with breathing during photon stereotactic ablative radiotherapy (SABR) of the lung, including intra-and inter-fractional motion, has previously been performed 8. This showed that 19% of patients experienced significant variations in target position between the planning four-dimensional CT (4D-CT) and treatment, and also between SABR fractions. These variations could be clinically relevant for those most severely affected. They concluded that on-couch assessment of target motion associated with breathing should be performed at each treatment fraction, to identify those patients who might benefit from respiratory gating or adaptive radiotherapy.
We relied on CTV coverage as a metric to quantify geometric treatment accuracy. In this way, tracking errors (in 2-view and 1-view modality along the visible directions) and non-tracked tumor motion (in 1-view modality along the nonvisible direction and in 0-view) can be considered altogether and are effectively related to the adopted margins., Moreover, geometric tumor coverage is an essential requirement for dose coverage and our analysis could represent a preliminary examination for further investigation on dose distribution actually delivered to the CTV throughout the entire treatment taking into account the temporal interplay between the CTV motion inside the PTV and the temporal aspect of the actual dose delivery.
The safety margins adopted in our Institution ensured a median C95 greater that 95% in each LOT modality. This means that, considering the entire patient population, the margins met the coverage criterion of C95 ≥ 95%. Consequently, patient-specific margin optimization resulted in larger margins in less than 37% of patients considering all LOT modalities. In 2-view modality, larger margins are required in 30% of patients to compensate mostly for tracking errors. Indeed, in 2-view, C95 is strongly correlated with the overall tracking error (R = À0.9). Conversely, in 0-view modality C95 is strongly correlated with tumor motion measured during treatment (R = À0.8). Actually, 0-view modality is more sensitive to interfraction and intrafraction breathing pattern variations, which are likely to occur in patients with respiratory disease. Similar to our work, Descovitch et al. 12 evaluated target coverage simulating 0-view modality treatments and concluded that a uniform margin of 4.5 mm around the ITV was necessary to assure 95% target coverage for 95% of the fractions. With respect to Descovich et al., we further analysed target coverage in 1-and 2-view modality. In 1-view, C95, and consequently the optimal margin, depends on both tracking errors (R = À0.7) and respiratory motion (R = À0.6). However, in some patients, safety margins could be reduced still ensuring CTV coverage, while enhancing treatment conformality by sparing a larger volume of healthy tissues.
Irradiated volumes increases passing from 2-view to 1-view and 0-view modalities. Considering the same CTV coverage (C95 ≥ 95%), the use of 1-view of 0-view modalities instead of 2-view resulted in PTV enlarged by 36.6 AE 25.8% and 82.9 AE 101.2%, respectively.
The visibility of the target in the X ray images acquired during treatment (and thus the selection of the suitable motion management modality) depends on target size, density and location. The patients included in this study were treated with 2-view tracking modality; hence all lesions had characteristics that made them visible in both X ray images. The presented coverage analysis was then extended to simulated 1-view and 0-view modalities taking advantage of the complete 2-view tracking data extracted from the treatment log files. In clinical practice, the 1-view and 0-view modalities are selected when the lesions are too small, not sufficiently dense or when they overlap organs at risk (OAR) in the X ray projections. This could occur regardless of the type of patient's breathing motion. This means that the same lesion, characterized by the same movement during breathing, could turn out to be a 2-view, 1-view and 0-view case at varying its density and size resulting visible or not in the X ray images acquired during treatment. From this point of view, the coverage analysis performed in simulated 1-view and 0-view cases could be considered realistic. However, in 0-view treatments tissue shifts between spine and lesion could occur and their effect on CTV coverage cannot be considered in our analysis and specific further investigation is advisable.
In conclusion, safety margins allow compensating tracking errors and tumor motion in all LOT modalities ensuring adequate target coverage in the majority of patients. CTV coverage analysis provided an a-posteriori evaluation of the treatment geometric accuracy and allowed us to quantitatively verify the adequacy of the PTV margins applied in CyberKnife LOT treatments delivered at our Institution. Further investigations on dose distribution actually delivered to the CTV throughout the entire treatment will be addressed to fully evaluate the adequacy of safety margins.
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